ES2060698T3 - Ensayo para polimeros de fibrina entrelazada solubles. - Google Patents

Ensayo para polimeros de fibrina entrelazada solubles.

Info

Publication number
ES2060698T3
ES2060698T3 ES89111471T ES89111471T ES2060698T3 ES 2060698 T3 ES2060698 T3 ES 2060698T3 ES 89111471 T ES89111471 T ES 89111471T ES 89111471 T ES89111471 T ES 89111471T ES 2060698 T3 ES2060698 T3 ES 2060698T3
Authority
ES
Spain
Prior art keywords
fibrine
soluble
polymers
dimero
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89111471T
Other languages
English (en)
Inventor
Victor J Marder
Charles W Francis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Application granted granted Critical
Publication of ES2060698T3 publication Critical patent/ES2060698T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9726—Tissue plasminogen activator

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Multicomponent Fibers (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)

Abstract

LA INVENCION SE REFIERE A UN ENSAYO PARA POLIMEROS DE FIBRINA EN EL DIAGNOSTICO DE PACIENTES CON PELIGRO DE TROMBOSIS Y EN EL CONTROL DE LOS EFECTOS DEL TRATAMIENTO EN TALES PACIENTES. MAS PARTICULARMENTE, LA PRESENTE INVENCION SE REFIERE A UN ENSAYO PARA POLIMEROS DE FIBRINA RETICULADOS SOLUBLES EN MUESTRA DE PACIENTES QUE IMPLICAN EL TRATAMIENTO IN VITRO DE LA MUESTRA CON UNA ENZIMA PROTEOLITICA TAL COMO LA T - PA QUE GENERA EL FRAGMENTO DIMERO D, DE POLIMEROS DE FIBRINA SOLUBLES. PREFERIBLEMENTE SE DETERMINA LA CANTIDAD FORMADA DE DIMERO D, MEDIANTE UN INMUNOENSAYO ESPECIFICO PARA EL DIMERO D. LA MEDIDA DEL DIMERO D ES ASI UN REFLEJO UTIL DEL ESTADO DE HIPERCOAGUBILIDAD Y EL ENSAYO PUEDE SER UTIL PARA ESTABLECER ALTERACIONES PRETROMBOTICAS O TROMBOTICAS TAL COMO EL INFARTO DE MIOCARDI, EMBOLIA PULMONAR Y TROMBOSIS EN VENA PROFUNDA, ASI COMO PARA LA FORMACION DE FIBRINA SOLUBLE EN ESTADOS NEOPLASICO, INMUNE, INFLAMATORIO, O OTRAS CONDICIONES PATOLOGICAS Y PARA EVALUACIONES DE TERAPIA TALES COMO CON LAS ANTICOUGULANTES QUE SE USAN PARA TRATAR ESTAS CONDICIONES.
ES89111471T 1988-06-24 1989-06-23 Ensayo para polimeros de fibrina entrelazada solubles. Expired - Lifetime ES2060698T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21357288A 1988-06-24 1988-06-24

Publications (1)

Publication Number Publication Date
ES2060698T3 true ES2060698T3 (es) 1994-12-01

Family

ID=22795625

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89111471T Expired - Lifetime ES2060698T3 (es) 1988-06-24 1989-06-23 Ensayo para polimeros de fibrina entrelazada solubles.

Country Status (8)

Country Link
EP (1) EP0347933B1 (es)
JP (1) JP2657417B2 (es)
AT (1) ATE111532T1 (es)
DE (1) DE68918170T2 (es)
DK (1) DK313889A (es)
ES (1) ES2060698T3 (es)
IE (1) IE67430B1 (es)
PT (1) PT90941B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453359A (en) * 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
FR2703788B1 (fr) * 1993-04-09 1996-12-20 Jacques Toledano Dispositif et procede anti-idiotype de detection immunologique.
SE9403833D0 (sv) * 1994-11-08 1994-11-08 Global Hemostasis Inst Mgr Ab Analysförfarande och kit
FR2813395B1 (fr) * 2000-08-28 2003-01-24 Stago Diagnostica Methode de dosage in vitro de la fibrine soluble par generation de produits de degradation specifiques
MXPA03012030A (es) 2001-06-26 2005-07-01 Agen Biomedical Ltd Anticuerpos humanizados derivados de dd-3b6/22, especificos para el fragmento de dimero d de fibrina.
DE10247876A1 (de) * 2002-10-14 2004-05-13 Aventis Behring Gmbh Intellectual Property/Legal Verfahren zur Bestimmung von Multimeren von Plasmaproteinen
WO2006118195A1 (ja) 2005-04-28 2006-11-09 Mitsubishi Kagaku Iatron, Inc. 安定化フィブリンのプラスミン分解物の免疫学的分析方法
FR2900734B1 (fr) * 2006-05-05 2009-03-06 Diagnostica Stago Soc Par Acti Detection des maladies veineuses thromboemboliques par le dosage des d-dimeres et de la fibrine soluble
CN110007094B (zh) * 2019-04-29 2022-04-05 江苏众红生物工程创药研究院有限公司 人d-二聚体定量检测卡及其临床应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572125B2 (en) * 1983-03-17 1988-05-05 Mabco Limited Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses
DE3430906A1 (de) * 1984-08-22 1986-02-27 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur bestimmung von fibrinmonomer in plasma
AU7912887A (en) * 1986-08-25 1988-03-24 American Biogenetic Sciences, Inc. Monoclonal antibodies to fibrin

Also Published As

Publication number Publication date
DE68918170T2 (de) 1995-03-02
DK313889A (da) 1989-12-25
PT90941B (pt) 1994-11-30
EP0347933B1 (en) 1994-09-14
JPH02112763A (ja) 1990-04-25
IE892010L (en) 1989-12-24
IE67430B1 (en) 1996-04-03
PT90941A (pt) 1989-12-29
JP2657417B2 (ja) 1997-09-24
DE68918170D1 (de) 1994-10-20
ATE111532T1 (de) 1994-09-15
EP0347933A2 (en) 1989-12-27
DK313889D0 (da) 1989-06-23
EP0347933A3 (en) 1990-10-17

Similar Documents

Publication Publication Date Title
Stalder et al. Release of vascular plasminogen activator (v‐PA) after venous stasis: electrophoretic—zymographic analysis of free and complexed v‐PA
DK36991A (da) Vaevsplasminoaktivator-(t-pa)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmaade til fremstilling deraf, dna-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og vaertsceller transformeret med vektoren
ES2060698T3 (es) Ensayo para polimeros de fibrina entrelazada solubles.
Budzynski et al. Fibrinogenolytic afibrinogenemia after envenomation by western diamondback rattlesnake (Crotalus atrox)
Kim et al. Direct acting anti-thrombotic serine protease from brown seaweed Costaria costata
Wang et al. Latent and active plasminogen activator in corneal ulceration.
Booth et al. Plasmin‐a2‐antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis
SE8301794D0 (sv) Plasminogenaktivatorkomplex
ATE15071T1 (de) Verfahren zur herstellung eines aus blutbahnen gewonnenen aktiven fibrinolytischen prinzips sowie das so hergestellte enzym.
Lenich et al. Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture
Minix et al. Interaction of fucoidan with proteases and inhibitors of coagulation and fibrinolysis
ES553803A0 (es) Procedimiento para determinar un activador de plasminogeno
Knox et al. Role of plasminogen, plasmin, and plasminogen activators in the migration of fibroblasts into plasma clots
Matsuo et al. Effect of urinary trypsin inhibitor on osteoarthritis
Sultan et al. A dynamic test to investigate potential tissue plasminogen activator activity Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients
Pawlak et al. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity
NO166314B (no) Fremgangsmaate for fremstilling av en plasminogenaktivatoravledet fra human nyre.
Hayashi et al. Role of α2-plasmin inhibitor in the appearance of fibrinolytic activity during urokinase administration, and an evaluation of the optimal urokinase dosage
Balkuv-Ulutin Fibrinolytic system in atherosclerosis
Chang et al. Integrin αvβ3 and phospholipase C regulate prostacyclin formation of endothelial cells caused by ancrod-generated fibrin
Levit et al. Posttraumatic punctate hemorrhage of the skin: a better name than black heel
Kluft New prospects in the activation of fibrinolysis
ATE90394T1 (de) Bestimmungstest fuer der thrombose verwandte materialien.
Ablin Antiepithelial antibodies in prostatic cancer
Hong et al. Effect of nerve block on t-PA release by venous occlusion

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 347933

Country of ref document: ES